Telix Pharmaceuticals (TLX) Common Equity (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Common Equity for 3 consecutive years, with $415.4 million the latest figure, recorded in Q4 2025.

• Quarterly Common Equity rose 3.51% year-over-year to $415.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $415.4 million (up 3.51% YoY) and the FY2025 annual result came in at $415.4 million, up 17.69% from the prior year.
• Common Equity climbed to $415.4 million in Q4 2025 per TLX's latest filing, from $401.3 million in the prior quarter.
• Over the last five years, Common Equity for TLX reached as high as $415.4 million in Q4 2025 and fell as low as $105.2 million in Q4 2023.
• A 3-year average of $307.3 million and a median of $401.3 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity surged 281.58% — and 2025, when it rose 3.51%.
• Year by year, Common Equity stood at $105.2 million in 2023, then jumped by 281.58% to $401.3 million in 2024, then grew by 3.51% to $415.4 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $415.4 million, $401.3 million, and $105.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.